Munich, October 27, 2011 / B3C newswire / - Bioiberica, one of the world's leading companies in the field of joint health, is now active in Germany: starting immediately, trading by Bioiberica GmbH is being controlled from the new head office in Munich. The company has been researching, developing, producing and marketing pharmaceuticals and dietary substances of the highest quality for more than 35 years. Bioiberica was founded in 1975 in Barcelona, Spain, and is now present in more than 70 countries world-wide.
One of Bioiberica's main focuses is on the field of osteoarthritis. "Doctors and patients all over the world put their trust in our broad product portfolio of chondroprotectives, such as chondroitin sulphate, glucosamine and hyaluronic acid. We are very pleased that we will soon be making our first contribution to the dietary care of patients with osteoarthritis with our first product in Germany" explained Axel Schmidt, pharmacist and Division Director of Bioiberica GmbH. The company has not only made a name for itself wtih chondroprotectives, but also with the research and development of heparins.
The efficacy and safety of the Bioiberica products have been proved in comprehensive clinical trials as well as in numerous international articles and publications.
Scientific expertise – holistic approach to osteoarthritis
Bioiberica provides doctors and patients with a broad spectrum of health solutions for the symptoms of osteoarthritis. The company thereby follows a holistic approach:
- Early diagnosis and prevention – genetic tests
- Dietary supply & pharmacotherapy – innovative chondroprotectives
- Personalised medicine – pharmacogenetics & cell therapy
Research & development spans from personalised diagnostics (including biomarkers) to prevention and medication-based treatment right up, to dietary care for patients with osteoarthritis and other joint problems.
Research, production and innovation with experience
Bioiberica has been manufacturing high-quality products for the pharmaceutical, veterinary, and food industries on the basis of biomolecules for over 35 years. The special medical and scientific departments at Bioiberica have registered 17 new patents over the last 10 years. The company is currently supporting 36 research projects, 18 of which are in the field of joint protection. Every year Bioiberica invests more than 6 million EUR in the research and development of new biomolecules. The production processes are subject to stringent, self-imposed manufacturing standards that are regularly certified by notable institutes (ISO 9001, ISO 14001, OSHAS 18001, EMAS and SA 800). For example, Bioberica's highly specialised expert staff developed the product CSbBIO-ACTIVE®, the best-researched chondroitin sulphate with the highest available degree of purity.
Part of the world-wide scientific network
Every year, Bioiberica hosts various international scientific symposia at the major congresses for rheumatology and orthopaedics. In this way, the company promotes the global transfer of knowledge and maintains long-term co-operation with leading international research institutions. Our common aim: to develop new biomolecules that ensure an enduring improvement in quality of life and to breathe life into new ideas.
Health solutions and committment to protecting the environment
An important element in Bioiberica's corporate philosophy is to equip doctors and other healthcare professionals with the instruments and knowledge they require for a needs-based patient care and treatment. So Bioiberica provides doctors and other specialists with service materials and products for the diagnosis, prevention and treatment of osteoarthritis and other joint diseases and symptoms.
Incidentally, Bioiberica is one of the first pharmaceutical companies to have integrated the environmental guidelines as a central module in its corporate policy and to adapt its production processes to the ecological balance. For instance, the company invests about 2.5% of its sales in environmental protection alone.
Background information on osteoarthritis
Osteoarthritis is the most common joint disease in the world. About 190 million people (10 - 15% of the total population) suffer from this disease; 60 million of these patients are in Europe alone, with 5 million in Germany. The percentage of females affected is considerably higher: 68% of women over 65 have osteoarthritis.
Osteoarthritis describes the condition following the destruction of the catrilage layer in a joint and the associated bony changes. The pathophysiology has still not been completely explained. However, three different stages of development can usually be recognised:
- Destruction of the cartilage
- Inflammation of the synovial membrane
- Subchondral bone degeneration
Possible risk factors for osteoarthritis include hereditary predisposition, congenital deformities of the joints, injuries, long-term overuse and metabolic diseases.
While osteoarthritis has usually been considered the result of wear and tear to date – a sort of unavoidable fate – new findings in pathophysiology have shown real possibilities for effective therapeutic intervention.
For further information:
Tel.: +49 (0)89 452 352 142
Fax: +49 (0)89 452 352-110
Anne Schardey/Rosmarie Dammler
Tölzer Straße 12
Tel.: +49 (0)8024 47013 - 0
Fax: +49 (0)8024 47013-20